Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

1200

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

DRUG: R-mabHDI and ABVD
DRUG: ABVD

Sponsor

American Scitech International

Collaborators

[object Object]
[object Object]